Business Daily Media

Business Marketing

.

Eisai: Final Study Results Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress

  • Written by ACN Newswire - Press Releases

image

TOKYO, Oct 1, 2019 - (JCN Newswire) - Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (NYSE: MRK), known as MSD outside the United States and Canada, announced final results from the full endometrial cancer cohort of KEYNOTE- 146/Study 111 evaluating LENVIMA, an orally available kinase inhibitor discovered by Eisai , plus KEYTRUDA,

Read more //?#

Popular

5 Business Ideas For Students And Entrepreneurs

Kickstarting a business and running it successfully is not a walk in the park. However, that shouldn’t put you off from starting a venture on your own. With the right attitude, you can definitely leave your mark in the world. ...

6 Strategies to help get your bad credit car loan over the line

There could be a number of reasons why you have bad credit – from missing payments or defaulting on previous loans, to not having any history of using credit. If you’re looking to get a bad credit car loan, you might be feeling ...

Illness on holidays

Well balanced diet It is a fact that everyone should eat a well-balanced diet every day. Among those who suffer if they don’t have well-balanced diets are growing children. Those who are the most at risk include women who are p...